Skip to main content
JUBLPHARMA · Health Care · 2026-08-21

Jubilant Pharmova Ltd

Stage 4 · wk 2In scan: Breakout WatchMARKET: BULL RISING · 2026-08-21
₹880.4
+1.07% today
₹13,944 Cr · Mid cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. The company serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.

Visit company website →
P/E (TTM)
39.5
Forward 19.5
Earnings Growth (YoY)
-22.4%
Revenue +18.7%
ROE
+6.0%
Profit margin +4.8%
Dividend Yield
0.51%
P/B 2.4
vs 52W High
-25.5%
₹807.7 lo₹1,181.2 hi
25.5% below 52W high — ongoing decline
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 2
1w13w26w
Week 2 — early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-9.7%
200 DMA: ₹974.9 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
1.27x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
MA20 rolling over · -5.4% vs MA50 -2.8%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
Sector has 84 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Industry has 58 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-29 → 2026-08-21
S2 18w
S2 53w
S4 16w
2023-05-292026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 4w → S2 18w → S3 6w → S2 53w → S3 11w → S4 11w → S1 5w → S2 8w → S3 10w → S2 5w → S3 5w → S4 16w → S1 12w → S4 2w current
Total tracked: 167 weeks across 14 stage runs.
1M
-9.3%
3M
-12.5%
6M
-1.6%
YTD
-16.4%
1Y
-18.3%
Scan Membership
Breakout Watch
Latest: 2025-11-10
2 appearances in last 60 days. First seen: 2025-07-02.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S4
Wk 2 · Vol x
2026-08-20S4
Wk 2 · Vol x
2026-08-19S4
Wk 2 · Vol x
2026-08-18S4
Wk 2 · Vol x
2026-08-17S4
Wk 2 · Vol x
2026-08-14S4
Wk 1 · Vol x
2026-08-13S4
Wk 1 · Vol x
2026-08-12S4
Wk 1 · Vol x
2026-08-11S4
Wk 1 · Vol x
2026-08-10S41→4
Wk 1 · Vol x
2026-08-07S1
Wk 13 · Vol x
2026-08-06S1
Wk 12 · Vol x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹956.5
200 DMA
₹974.9
52W High
₹1,181.2
52W Low
₹807.7
5D Low
₹866
Resistance levels (recent highs)
20d High
₹979.7
60d High
₹1,028.4
120d High
₹1,028.4
250d High
₹1,181.2
Next resistance
+11.3%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.